Search

everythinglearnresearchcommunity

for

Search:↓

Women with irregular periods should be checked for PCOS and treated early to prevent complications, with birth control pills helping to manage symptoms.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

Women with excess body hair feel psychological distress influenced by societal beauty standards, but distress isn't directly linked to the amount of hair.

Certain gene variants may contribute to high androgen levels in women with polycystic ovary syndrome.

Isotretinoin improves severe acne without changing androgen or insulin levels but may increase body weight and triglycerides.

The type of PCOS a woman has doesn't strongly predict her skin or metabolic symptoms; obesity is a more important factor.

Women with idiopathic hirsutism and PCOS have higher RBP4 levels, and PCOS is linked to greater insulin resistance; weight management may help both conditions.

Acupressure improves quality of life in PCOS patients.

Eating disorders can cause various hair problems, and while hair loss in these disorders is linked to metabolic syndrome, treatment focuses on specific medications and lifestyle changes for the syndrome.

Women with the NIH type of PCOS have more obesity and higher risk of diabetes and heart disease than those with other types of PCOS.

Insulin resistance and obesity are key factors in the development and worsening of polycystic ovary syndrome, and lifestyle changes are important for managing it.

Antiandrogen treatments combined with oral contraceptives can help manage hair growth and hair loss in women with PCOS.

To diagnose Polycystic Ovarian Syndrome, two out of three signs—irregular periods, high male hormone levels, or cysts on the ovaries—are needed.

Women with PCOS are more likely to have insulin resistance and obesity, especially those with the most severe type I PCOS.

The document concludes that correct diagnosis and management of PCOS are important, and more research is needed on its risks and treatments.

The PCOSQ-50 is a valid and reliable questionnaire for measuring quality of life in Iranian women with PCOS.

Teens with PCOS and a mom with PCOS have higher insulin resistance and lower adiponectin levels, which could signal early metabolic problems.

Polycystic Ovary Syndrome can cause hair loss and skin issues, and early treatment is important for preventing complications.

Women with PCOS have more emotional and body image issues than healthy women.

Unwanted facial hair significantly impacts over 40% of women's psychological and social well-being, and various treatment options are available.

Obese women had more testosterone and less acne, but similar hair growth compared to non-obese women.

The Chinese version of the PCOS quality of life questionnaire is reliable and valid for Chinese-speaking women with PCOS.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

About 5% of Thai university girls aged 17-19 have polycystic ovary syndrome, with moderate acne being a strong risk factor.

The document concludes that managing PCOS involves treating symptoms and reducing long-term metabolic risks, with lifestyle changes being important.

Women with congenital adrenal hyperplasia (CAH) have more sexual function issues than those with polycystic ovary syndrome (PCOS), but physical activity can improve sexual functioning in all women.

Women with excessive hair growth often have hormonal issues and need medical advice and treatment.

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

Late diagnosis of congenital adrenal hyperplasia can greatly affect physical development, gender identity, and sexual health.

Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.